The role of interleukin-6 in development and progression of atherosclerosis;Rola interleukiny 6 w wysta̧pieniu i progresji miażdżycy

Polski Merkuriusz Lekarski

Volumn 22, Issue 130, 2007, Pages 291-294

  Dubiński, Andrzej ^a,c   Zdrojewicz, Zygmunt ^b,d,e  

^a Szpital Powiatowy   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c District Hospital   (Poland)

^d UNIVERSITY OF WROC AW   (Poland)

^e Katedra i Klinika Endokrynologii   (Poland)

Author keywords

Atherosclerosis; Coronary heart disease; Interleukin 6

Indexed keywords

INTERLEUKIN 6;

ATHEROSCLEROSIS; CLINICAL TRIAL; DISEASE COURSE; HUMAN; METABOLISM; PREDICTION AND FORECASTING; REVIEW; RISK FACTOR;

ATHEROSCLEROSIS; CLINICAL TRIALS; DISEASE PROGRESSION; HUMANS; INTERLEUKIN-6; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 34249669178     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Bautista L.E., Vera L.M., Arenas I.A. i wsp.: Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNFalpha) and essential hypertension. J. Hum. Hypertens., 2005, 19, 149-154.
2. Bermudez E.A., Rifai N., Buring J. i wsp.: Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler. Thromb. Vasc. Biol., 2002, 22, 1668-1673.
3. Burstein S.A.: Effects of interleukin 6 on megakaryocytes and on canine platelet function. Stem Cells, 1994, 12, 386-393.
4. Cappola A.R., Xue Q.L., Ferrucci L. i wsp.: Insulin-like growth factor I and interteukin-6 contribute synergistically to disability and mortality in older women. J. Clin. Endocrinol. Metab., 2003, 88, 2019-2025.
5. Castell J.V., Gomez-Lechon M.J., David M. i wsp.: Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett., 1989, 242, 237-239.
6. Cesari M., Penninx B.W., Newman A.B. i wsp.: Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation, 2003, 108, 2317-2322.
7. Escobar-Morreale H.F., Villuendas G., Botella-Carretero J.I. i wsp: Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women. Diabetologia, 2003, 46, 625-633.
8. Furnkranz A., Schober A., Bochkov V.N.: Oxidized phospholipids trigger atherogenic inflammation in murine arteries. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 633-638.
9. Garanty-Bogacka B., Syrenicz M., Syrenicz A. i wsp.: Serum markers of inflammation and endothelial activation in children with obesity-related hypertension. Neuro. Endocrinol. Lett., 2005, 26, 242-246.
10. Giuliani N., Sansoni P., Girasole G. i wsp.: Serum interleukin-6, soluble interleukin-6 receptor and soluble gp130 exhibit different patterns of ageand menopause-related changes. Exp Gerontol., 2001, 36, 547-557.
11. Głowińska B, Urban M.: Wybrane cytokiny (IL-6, IL-8, IL-10.MCP-11 TNFct) u dzieci i młodzieży obarczonych tradycyjnymi czynnikami ryzyka miażdżycy: otylościq, nadciśnieniem, cukrzyca̧. Wiad Lek., 2003;56(3-4), 109-116.
12. Gwechenberger M, Mendoza L.H., Youker K.A., i wsp.: Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. Circulation, 1999, 99, 546-551.
13. Halawa B, Salomon P, Jolda-Mydlowska B i wsp.: Stȩżenia czynnika martwicy nowotworów (TNF-alfa) i interleukiny 6 (IL-6) w surowicy chorych na świeży zawal miȩśnia serca. Pol. Arch. Med. Wewn., 1999 Mar, 101(3), 197-203.
14. Hartford M., Wiklund O., Mattsson Hulten L. i wsp.: CRP, interleukin-6, secretory phospholipase A2 group IIA, and intercellular adhesion molecule-1 during the early phase of acute coronary syndromes and long-term follow-up. Int. J. Cardiol., 2006, 108, 55-62.
15. Ikeda U., Ohkawa F., Seino Y. i wsp.: Serum interteukin 6 levels become elevated in acute myocardial infarction. J. Mol. Cell. Cardiol., 1992, 24, 579-584.
16. James S.K., Lindahl B., Timmer J.R., i wsp.: Usefulness of biomarkers for predicting long-term mortality in patients with diabetes mellitus and non-ST-elevation acute coronary syndromes (a GUSTO IV substudy). Am. J. Cardiol., 2006, 97, 167-172.
17. Jones S.A., Horiuchi S., Topley N., Yamamoto N., Fuller G. M.: The soluble interleukin-6 receptor: mechanisms of production and implications in disease. FASEB J., 2001, 15, 43-58.
18. Kaser A., Brandacher G., Steurer W. iwsp.: Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood, 2001, 98, 2720-2725.
19. Kerr R., Stirling D., Ludlam C.A.: Interteukin 6 and haemostasis. Br. J. Haematol., 2001, 115, 3-12.
20. Khaodhiar L., Ling P.R., Blackburn G.L.. i wsp.: Serum levels of interleukin-6 and C-reactive protein correlate with body mass index across the broad range of obesity. JPEN J. Parenter. Enteral. Nutr., 2004, 28, 410-415.
21. Kishimoto T., Akira S., Narazaki M., i wsp.: Interleukin-6 family of cytokines and gp130. Blood, 1995, 86, 1243-1254.
22. Koukkunen H., Penttila K., Kemppainen A. i wsp.: C-reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-alpha in the prognostic classification of unstable angina pectoris. Ann. Med., 2001, 33, 37-47.
23. Libby P., Ridker P.R Maseri A.: Inflammation and Atherosclerosis. Circulation, 2002, 105, 1135-1146.
24. Lindmark E., Diderholm E., Wallentin L. i wsp.: Relationship between inteheukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA, 2001, 286, 2107-2113.
25. Mackiewicz H., Schooltink P.C., Heinrich S.: Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J. Immunol., 1992, 15, 149, 2021-2027.
26. Modur V., Li Y., Zimmerman G.A. i wsp.: Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor alpha. J. Clin. Invest., 1997, 100, 2752-2756.
27. Mohamed-Ali V., Goodrick S., Rawesh A .I. i wsp.: Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J. Clin. Endocrinol. Metab., 1997, 82, 4196-4200.
28. Oleksowicz L., Mrowiec Z., Zuckerman D. i wsp.: Platelet activation induced by interleukin-6: evidence for a mechanism involving arachidonic acid metabolism. Thromb. Haemost., 1994, 72, 302-308.
29. Panagiotakos D.B., Pitsavos C., Yannakoulia M. i wsp.: The implication of obesity and central fat on markers of chronic inflammation: The ATTICA study. Atherosclerosis, 2005, 183, 308-315.
30. Papanicolaou D.A., Wilder R.L., Manolagas S.C. i wsp.: The pathophysiologic roles of interleukin-6 in human disease. Ann. Intern. Med 1998, 15, 127-137.
31. Park H.S., Park J.Y., Yu R.: Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. Diabetes Res Clin Pract., 2005, 69, 29-35.
32. Podkówka R, Wiśniewska J, Korybalska K i wsp.: Stȩzenie II-6 i IL-8 w surowicy krwi zdrowych osób w wieku podesziym. Przegl Lek., 2002, 59, 230-233.
33. Pradhan A.D., Manson J.E., Rossouw J.E. i wsp., Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women 's Health Initiative observational study. JAMA, 2002, 288, 980-987.
34. Rachon D., Mysliwska J., Suchecka-Rachon K. i wsp.: Effects of oestrogen deprivation on interleukin-6 production by peripheral blood mononuclear cells of postmenopausal women. J. Endocrinol., 2002, 172, 387-395.
35. Ridker P.M., Rifai N., Stampfer M.J. i wsp.: Plasma Concentration of Interleukin-6 and the Risk of Future Myocardial Infarction Among Apparently Healthy Men. Circulation, 2000, 101, 767.
36. Romano M., Sironi M., Toniatti C. i wsp.: Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity., 1997, 6, 315-325.
37. Scheidt-Nave C., Bismar H., Leidig-Bruckner G.I. wsp.: Serum interleukin-6 is a major predictor of bone loss in women specific to the first decade past menopause. J. Clin. Endocrinol. Metab., 2001, 86, 2031-2042.
38. Silvestri A., Gebara O., Vitale C. i wsp.: Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response. Circulation, 2003,107, 3165-3169
39. Takabe W., Kanai Y., Chairoungdua A., i wsp., Lysophosphatidylcholine enhances cytokine production of endothelial cells via induction of L-type amino acid transporter 1 and cell surface antigen 4F2. Arterioscler. Thromb. Vase. Biol., 2004, 24, 1640-1645.
40. Vicennati V., Vottero A., Friedman C. i wsp.: Hormonal regulation of interleukin-6 production in human adipocytes. Int. J. Obes. Relat. Metab. Disord., 2002, 26, 905-911.
41. Visseren S.L., Verkerk M.S., Bouter K.P. i wsp.: Interleukin-6 production by endothelial cells after infection with influenza virus and cytomegalovirus. J. Lab. Clin. Med., 1999, 134, 623-630.
42. Vitale C., Cornoldi A., Gebara O. i wsp.: lnterleukin-6 and flow-mediated dilatation as markers of increased vascular inflammation in women receiving hormone therapy. Menopause, 2005, 12, 552-558.
43. Volk T., Hensel M., Schuster H. i wsp.: Secretion of MCP-1 and IL-6 by cytokine stimulated production of reactive oxygen species in endothelial cells. Mol Cell Biochem. 2000, 206, 105-112.
44. Walsh B., Cox D., Sashegyi A. i wsp.: Role of tumor necrosis factor-alpha and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women. Am. J. Cardiol., 2001, 88, 825-828.
45. Weiss C.R., Aral A.E., Bui M.N. i wsp.: Arterial wall MRI characteristics are associated with elevated serum markers of inflammation in humans. J. Magn. Reson. Imaging., 2001, 14, 698-704.